VEGF-D Antibody (C-12): sc-373866
- VEGF-D Antibody (C-12) is a mouse monoclonal IgG1 κ VEGF-D antibody, cited in 8 publications, provided at 200 µg/ml
- specific for an epitope mapping between amino acids 330-353 at the C-terminus of VEGF-D of human origin
- VEGF-D Antibody (C-12) is recommended for detection of precursor VEGF-D of human origin by WB, IP, IF and ELISA
- Anti-VEGF-D Antibody (C-12) is available conjugated to agarose for IP; HRP for WB, IHC(P) and ELISA; and to either phycoerythrin or FITC for IF, IHC(P) and FCM
- also available conjugated to Alexa Fluor® 488, Alexa Fluor® 546, Alexa Fluor® 594 or Alexa Fluor® 647 for WB (RGB), IF, IHC(P) and FCM, and for use with RGB fluorescent imaging systems, such as iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- also available conjugated to Alexa Fluor® 680 or Alexa Fluor® 790 for WB (NIR), IF and FCM; for use with Near-Infrared (NIR) detection systems, such as LI-COR®Odyssey®, iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for VEGF-D Antibody (C-12) for WB applications. These reagents are now offered in bundles with VEGF-D Antibody (C-12) (see ordering information below).
QUICK LINKS
VEGF-D Antibody (C-12) is a mouse monoclonal IgG1 kappa light chain antibody that detects VEGF-D protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). VEGF-D monoclonal antibody (C-12) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. VEGF-D protein, also known as FIGF, plays a crucial role in angiogenesis, which is the formation of new blood vessels from pre-existing ones. This process is vital not only for normal physiological functions such as wound healing and tissue repair but also in pathological conditions like cancer, where tumor growth and metastasis are facilitated by the development of a robust blood supply. The central region of VEGF-D contains eight cysteine residues that are essential for homodimerization, a structural feature that is critical for biological activity. Additionally, VEGF-D is induced by c-Fos, a transcription factor implicated in the progression of early-stage tumors to malignant forms. Overexpression of VEGF-D has been shown to induce significant morphological changes in fibroblasts, further highlighting potential role in tumor progression and importance in cancer research and therapeutic strategies.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
VEGF-D Antibody (C-12) References:
- Tumor angiogenesis: the role of oncogenes and tumor suppressor genes. | Bouck, N. 1990. Cancer Cells. 2: 179-85. PMID: 1696827
- The vascular endothelial growth factor family of polypeptides. | Ferrara, N., et al. 1991. J Cell Biochem. 47: 211-8. PMID: 1791185
- Angiogenic factors. | Folkman, J. and Klagsbrun, M. 1987. Science. 235: 442-7. PMID: 2432664
- Induction of angiogenesis during the transition from hyperplasia to neoplasia. | Folkman, J., et al. 1989. Nature. 339: 58-61. PMID: 2469964
- RAISEing VEGF-D's importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients. | Carmeliet, P., et al. 2018. Ann Oncol. 29: 527-529. PMID: 29360914
- Expression Profile of VEGF-C, VEGF-D, and VEGFR-3 in Different Grades of Endometrial Cancer. | Oplawski, M., et al. 2019. Curr Pharm Biotechnol. 20: 1004-1010. PMID: 31333122
- RAISEing VEGF-D's importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients. | Carmeliet, P., et al. 2018. Ann Oncol. 29: 529-532. PMID: 32139029
- Distinct Characteristics of VEGF-D and VEGF-C to Predict Mortality in Patients With Suspected or Known Coronary Artery Disease. | Wada, H., et al. 2020. J Am Heart Assoc. 9: e015761. PMID: 32319336
- VEGF-D-mediated signaling in tendon cells is involved in degenerative processes. | Tempfer, H., et al. 2022. FASEB J. 36: e22126. PMID: 35044682
- S100A6 drives lymphatic metastasis of liver cancer via activation of the RAGE/NF-kB/VEGF-D pathway. | Chen, T., et al. 2024. Cancer Lett. 587: 216709. PMID: 38350547
- Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. | Orlandini, M., et al. 1996. Proc Natl Acad Sci U S A. 93: 11675-80. PMID: 8876195
- Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. | Yamada, Y., et al. 1997. Genomics. 42: 483-8. PMID: 9205122
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
VEGF-D Antibody (C-12) | sc-373866 | 200 µg/ml | $322.00 | |||
VEGF-D Antibody (C-12): m-IgG Fc BP-HRP Bundle | sc-527420 | 200 µg Ab; 10 µg BP | $361.00 | |||
VEGF-D Antibody (C-12): m-IgG1 BP-HRP Bundle | sc-532793 | 200 µg Ab; 20 µg BP | $361.00 | |||
VEGF-D Antibody (C-12) AC | sc-373866 AC | 500 µg/ml, 25% agarose | $424.00 | |||
VEGF-D Antibody (C-12) HRP | sc-373866 HRP | 200 µg/ml | $322.00 | |||
VEGF-D Antibody (C-12) FITC | sc-373866 FITC | 200 µg/ml | $336.00 | |||
VEGF-D Antibody (C-12) PE | sc-373866 PE | 200 µg/ml | $349.00 | |||
VEGF-D Antibody (C-12) Alexa Fluor® 488 | sc-373866 AF488 | 200 µg/ml | $364.00 | |||
VEGF-D Antibody (C-12) Alexa Fluor® 546 | sc-373866 AF546 | 200 µg/ml | $364.00 | |||
VEGF-D Antibody (C-12) Alexa Fluor® 594 | sc-373866 AF594 | 200 µg/ml | $364.00 | |||
VEGF-D Antibody (C-12) Alexa Fluor® 647 | sc-373866 AF647 | 200 µg/ml | $364.00 | |||
VEGF-D Antibody (C-12) Alexa Fluor® 680 | sc-373866 AF680 | 200 µg/ml | $364.00 | |||
VEGF-D Antibody (C-12) Alexa Fluor® 790 | sc-373866 AF790 | 200 µg/ml | $364.00 | |||
VEGF-D (C-12) Neutralizing Peptide | sc-373866 P | 100 µg/0.5 ml | $69.00 |